The Dual Regulatory Framework: FDA and FTC

Health product advertising sits at the intersection of two distinct federal regulatory frameworks. The Food and Drug Administration regulates what claims can appear on product labels and packaging under the Federal Food, Drug, and Cosmetic Act and the Dietary Supplement Health and Education Act. The FTC regulates what claims can appear in advertising — in paid media, on websites, in social media posts, in sponsored content, and in any communication that promotes the product to consumers — under the FTC Act’s prohibition on unfair or deceptive practices. Both agencies care about accuracy, but they apply different standards, use different enforcement mechanisms, and coordinate imperfectly.

For practical purposes, the most important thing to understand about this dual framework is that a claim that might survive FDA scrutiny on a label does not automatically survive FTC scrutiny in advertising, and vice versa. The FTC has historically required that health claims in advertising be substantiated by competent and reliable scientific evidence, which the FTC has interpreted to mean randomized, controlled clinical trials in most cases involving disease prevention or treatment claims. The FDA applies a different and in some cases more elaborate standard for specific categories of claims. Compliance with one agency’s standards does not guarantee compliance with the other’s.

Categories of Health Claims

The FDA recognizes several distinct categories of health-related claims that can appear on dietary supplement and food labels, each with different substantiation and pre-approval requirements. Disease claims assert that a product prevents, treats, or cures a disease or health condition. Disease claims require FDA pre-approval through the new drug application process for drugs, or through the health claim notification process for foods. A supplement that claims to cure, treat, or prevent a disease is being marketed as a drug and must meet drug approval requirements — a standard almost no supplement can meet without clinical trial data of the type required for pharmaceutical approval.

Structure-function claims describe the role of a nutrient or ingredient in affecting the structure or function of the human body, without claiming to diagnose, treat, cure, or prevent any disease. Examples include calcium builds strong bones, fiber maintains bowel regularity, and vitamin C supports immune function. Structure-function claims for dietary supplements do not require FDA pre-approval but do require that the manufacturer notify FDA within 30 days of first marketing and include a specific disclaimer stating that the statement has not been evaluated by the FDA and that the product is not intended to diagnose, treat, cure, or prevent any disease.

Health claims for foods describe a relationship between a food substance and a disease or health-related condition. Authorized health claims are those that FDA has approved or recognized based on significant scientific agreement. Qualified health claims may be made based on credible scientific evidence that does not meet the significant scientific agreement standard, but must include qualifying language that accurately communicates the level of scientific support. The distinction between structure-function claims and health claims is one of the most frequently litigated boundary issues in dietary supplement and food marketing.

The FTC’s Substantiation Standard for Health Claims

The FTC requires that health claims in advertising be substantiated by competent and reliable scientific evidence before the claim is made. For claims involving health benefits, the FTC has generally interpreted this standard to require well-designed, randomized, controlled human clinical trials. Observational studies, animal studies, in vitro research, and the mere existence of a plausible biological mechanism are not sufficient to substantiate a clinical efficacy claim under the FTC’s standard. The FTC has brought numerous enforcement actions against dietary supplement and health product companies whose advertising claims were based on evidence that fell short of this standard.

The substantiation must exist before the claim is made. A company that makes a health benefit claim and then commissions a clinical trial to generate supporting evidence has not substantiated the claim at the time it was made and is violating the FTC’s substantiation requirement. The evidence supporting the claim must pre-exist the claim, must be of the type that experts in the relevant field would consider reliable and valid for the specific claim being made, and must actually demonstrate the specific effect being claimed for the specific product and dosage being marketed.

The Structure-Function Line in Advertising

The distinction between a permissible structure-function claim and an impermissible disease claim is not always clear in advertising. A product marketed to support cardiovascular health is making a structure-function claim. A product marketed to reduce the risk of heart attack or to treat high cholesterol is making a disease claim. The former is permissible for a supplement with appropriate substantiation and the required disclaimer; the latter requires drug approval. In practice, the line between these categories is frequently blurred by marketers who want the persuasive power of a disease claim while trying to stay within the legal space of a structure-function claim.

The FTC and FDA both look at the net impression of the advertising, not just the literal words of the claim. Consumer testimonials, before-and-after imagery, disease-related iconography, and descriptions of the conditions the product will help the consumer avoid can all contribute to a net impression of a disease claim even when the explicit claim language is framed in structure-function terms. Advertising that uses disease-related imagery and language while technically stopping short of an explicit disease claim may still be found to imply a disease claim, and the FTC will evaluate the advertising as a whole rather than parsing individual sentences.

Testimonials and Before-and-After Claims

Consumer testimonials for health products must meet the FTC’s Endorsement Guide requirements, including the requirement that testimonials reflect the typical results a consumer can expect, not just the best-case outcomes. Health product testimonials that describe dramatic improvements — significant weight loss, elimination of chronic pain, reversal of age-related conditions — must be either representative of typical results or accompanied by clear disclosure that results are not typical, along with disclosure of what typical results actually are. The FTC has been particularly aggressive in enforcement against health product testimonial advertising that features exceptional results without adequate disclosure.

Before-and-after photography and video in health product advertising are subject to the same substantiation and typical results requirements. Images that depict transformative physical changes must represent outcomes that are achievable by a typical consumer using the product as directed, without other significant lifestyle changes unless those changes are disclosed and included in the described routine. Before-and-after images that are achieved through lighting, posing, professional makeup, or post-processing without disclosure, and that are presented as representing the product’s effect, are deceptive.

FTC Enforcement Against Health Product Marketers

The FTC has consistently identified health product advertising as one of its highest enforcement priorities. Enforcement actions against dietary supplement companies, weight loss product marketers, anti-aging product sellers, and cognitive enhancement product advertisers have resulted in hundreds of millions of dollars in consumer redress and civil penalties over the past two decades. The FTC’s enforcement strategy has focused on unsubstantiated efficacy claims, misleading testimonials, false clinical trial citations, and implied disease claims in structure-function advertising.

A critical feature of FTC health product enforcement is that it frequently targets not just the brand selling the product but also the advertising agencies, media companies, and endorsers who participated in creating or distributing the deceptive advertising. Endorsers who make false health claims in advertising without disclosing their relationship with the brand, celebrities who promote health products without disclosing compensation, and influencers who make unsubstantiated efficacy claims without adequate disclosure have all been named in FTC enforcement actions. The entire distribution chain for deceptive health advertising faces potential FTC scrutiny, not just the product manufacturer.

Building a Compliant Health Product Marketing Program

For businesses that market dietary supplements, functional foods, or OTC health products, a compliant marketing program requires integrating scientific review and legal review into the claims development process before any advertising is created or published. Every efficacy claim must be reviewed against the existing scientific literature to determine whether adequate substantiation exists. Claims that cannot be substantiated by competent and reliable scientific evidence cannot be made, regardless of the marketing team’s enthusiasm for the claim or the anecdotal evidence that seems to support it.

The required FDA disclaimer — that statements have not been evaluated by the FDA and that the product is not intended to diagnose, treat, cure, or prevent any disease — must appear on all supplement labels and must be included in advertising that makes structure-function claims. The disclaimer must be clear and conspicuous, not buried in fine print or spoken too quickly to be understood in a broadcast advertisement. A marketing program that treats the disclaimer as an obstacle to be minimized rather than as a required communication to consumers is creating legal risk, because inadequate presentation of the disclaimer can contribute to a finding that the advertising creates a false net impression of disease claim efficacy that the disclaimer does not adequately correct.

See Also